Laimei pharmaceutical industry will combine industry and finance for development this year

[China Pharmaceutical network enterprise news] Laimei Pharmaceutical Co., Ltd released its 2017 annual report and 2018 first quarter report on April 21 Last year, the company achieved operating revenue of 1.282 billion yuan, a year-on-year increase of 29.47%; net profit of 55.5615 million yuan, a year-on-year significant increase of 695.88% It is reported that the reasons for the substantial growth of the company's performance are as follows: first, the product structure is further optimized, especially the sales growth of special specialty products, which makes the revenue and overall gross profit rate rise; in addition, in 2016, the company made a net profit of only 6 million 981 thousand and 100 yuan due to the provision for impairment of Argos stock From January to March this year, the company achieved an operating revenue of 327 million yuan, a year-on-year increase of 32.72%; and a net profit of 45.5631 million yuan, a year-on-year increase of 108.31% There are two main reasons for the big increase in performance: first, the company increased its marketing efforts, continued to optimize its product structure, and continued to improve its revenue and gross profit margin; at the same time, the sale of some of its shares in athenex generated an investment income of about 25.3598 million yuan It is understood that last year, Laimei pharmaceutical industry fully mobilized market advantage resources, strengthened professional promotion, improved product planning and academic level, accelerated product structure adjustment, increased sales of specialty drugs, implemented refined marketing mode, and realized the improvement of product profitability In terms of regions, the company's revenue growth mainly comes from East China and southwest China, of which, the sales revenue in East China increased by 99.4348 million yuan year-on-year, and the sales revenue in Southwest China increased by 50.1268 million yuan year-on-year In terms of product categories, the growth rate of specialty products is relatively fast, with a year-on-year growth of 50.82% Looking forward to 2018, Laimei pharmaceutical said that it will continue to promote the strategy of large varieties, through efforts to improve the quality of sales and service, increase the market development efforts of hospitals at all levels, actively layout the retail market outside the hospital in some regions, seize the market opportunities, and strive to maintain rapid growth of key products Among them, while deeply exploring the thyroid field, carnaline will actively promote the sales volume of breast, gastrointestinal and other fields, and further consolidate the monopoly position in the subdivision field; laimeishu will focus on the blank area, layout the hospital market at all levels, and further improve the market share In addition, the company will also strengthen the construction of sales team, improve the marketing incentive mechanism, optimize the marketing mode, and build a medical service platform with core competitiveness focusing on the advantageous fields In the context of changes in the pharmaceutical industry, the company will also actively integrate core resources and promote industrial transformation and upgrading with the help of capital market This year, the company will continue to give full play to the professional advantages of the industrial M & A fund that has been invested and established, actively introduce advanced products and technologies with market prospects, enrich the product structure, and lay out the targets or projects in line with the company's strategic development; At the same time, through intellectual property fund, project screening will be carried out around the field of biomedicine, and frontier fields will be laid out in advance to strive for breakthrough progress in project screening Original title: Laimei pharmaceutical will combine industry and finance for development this year reporter: Wang Yi